Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT)
Identifieur interne : 000299 ( France/Analysis ); précédent : 000298; suivant : 000300Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT)
Auteurs : H. Allain [France] ; J. Cougnard [France] ; H-C. Neukirch [France]Source :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1991-10.
English descriptors
- KwdEn :
Abstract
The French selegiline multicenter trial was conducted in 1990 to test the possibility to improve disability of de novo parkinsonian patients (P. P.) during the first three months of treatment with selegiline (S) (10 mg/day) monotherapy. 93 P. P. were included in this double‐blind, randomized, placebo controlled, clinical trial, in which 13 centers participated. Both parallel groups were followed up from inclusion (D0) to D30, D60 and D90. Drug efficacy was judged with Hoehn and Yahr (HY), Hamilton Depression Rating Scale (HDRS), Unified Parkinson's Disease Rating Scale (UPDRS), Schwab and England scores, decision to introduce levodopa and selfassessment. Biological and clinical parameters (cardio‐ vascular, weight, side‐effects reports) were assessed for tolerability. 84 P. P. (38 P, 46 S) were evaluable for efficacy at D90. When considering the main parameters, S appears superior to placebo: HY scores (p < 0.001), global UPDRS scores (p < 0.001) and UPDRS subscores: mental (p < 0.001), daily living activities (p < 0.01), motor activities (p < 0.01). Depressive scores (HDRS) are significantly improved only at D90 (p=0.005). Levodopa therapy was introduced in 45 % of the cases in S groups versus 18,4 % in P group. Global impression of efficacy was largely in favor of S; failure was noted in half of the cases in P group and only in 1/5th of the cases in S group. Side‐effects were rare and minor. S 10 mg/day monotherapy is statistically superior to placebo in improving de novo P. P. during the first three months treatment. Motor symptoms rapidly improve; mood is only modified after 3 months. S appears to be well tolerated. S may be considered as a good candidate for the initial treatment of P. P.
Url:
DOI: 10.1111/j.1600-0404.1991.tb05024.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: 001A03
- to stream Main, to step Curation: 001750
- to stream Main, to step Exploration: 002682
- to stream France, to step Extraction: 000299
Links to Exploration step
ISTEX:28655FDC6F1264C54FEFD8055B0D549CF08F5B32Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT)</title><author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name></author><author><name sortKey="Cougnard, J" sort="Cougnard, J" uniqKey="Cougnard J" first="J." last="Cougnard">J. Cougnard</name></author><author><name sortKey="Neukirch, H" sort="Neukirch, H" uniqKey="Neukirch H" first="H-C." last="Neukirch">H-C. Neukirch</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:28655FDC6F1264C54FEFD8055B0D549CF08F5B32</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1111/j.1600-0404.1991.tb05024.x</idno><idno type="url">https://api.istex.fr/document/28655FDC6F1264C54FEFD8055B0D549CF08F5B32/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001A03</idno><idno type="wicri:Area/Main/Curation">001750</idno><idno type="wicri:Area/Main/Exploration">002682</idno><idno type="wicri:Area/France/Extraction">000299</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT)</title><author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Hopital Pontchaillou, Rennes</wicri:regionArea><placeName><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Cougnard, J" sort="Cougnard, J" uniqKey="Cougnard J" first="J." last="Cougnard">J. Cougnard</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Schering Plough, Levallois‐Perret</wicri:regionArea><wicri:noRegion>Levallois‐Perret</wicri:noRegion><wicri:noRegion>Levallois‐Perret</wicri:noRegion></affiliation><affiliation><wicri:noCountry code="subField">F</wicri:noCountry></affiliation></author><author><name sortKey="Neukirch, H" sort="Neukirch, H" uniqKey="Neukirch H" first="H-C." last="Neukirch">H-C. Neukirch</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Schering Plough, Levallois‐Perret</wicri:regionArea><wicri:noRegion>Levallois‐Perret</wicri:noRegion><wicri:noRegion>Levallois‐Perret</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1991-10">1991-10</date><biblScope unit="volume">84</biblScope><biblScope unit="issue">S136</biblScope><biblScope unit="page" from="73">73</biblScope><biblScope unit="page" to="78">78</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">28655FDC6F1264C54FEFD8055B0D549CF08F5B32</idno><idno type="DOI">10.1111/j.1600-0404.1991.tb05024.x</idno><idno type="ArticleID">ANE73</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MAO</term><term>Parkinson's disease</term><term>clinical trial</term><term>deprenyl</term><term>dopamine</term><term>early treatment</term><term>selegiline</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The French selegiline multicenter trial was conducted in 1990 to test the possibility to improve disability of de novo parkinsonian patients (P. P.) during the first three months of treatment with selegiline (S) (10 mg/day) monotherapy. 93 P. P. were included in this double‐blind, randomized, placebo controlled, clinical trial, in which 13 centers participated. Both parallel groups were followed up from inclusion (D0) to D30, D60 and D90. Drug efficacy was judged with Hoehn and Yahr (HY), Hamilton Depression Rating Scale (HDRS), Unified Parkinson's Disease Rating Scale (UPDRS), Schwab and England scores, decision to introduce levodopa and selfassessment. Biological and clinical parameters (cardio‐ vascular, weight, side‐effects reports) were assessed for tolerability. 84 P. P. (38 P, 46 S) were evaluable for efficacy at D90. When considering the main parameters, S appears superior to placebo: HY scores (p < 0.001), global UPDRS scores (p < 0.001) and UPDRS subscores: mental (p < 0.001), daily living activities (p < 0.01), motor activities (p < 0.01). Depressive scores (HDRS) are significantly improved only at D90 (p=0.005). Levodopa therapy was introduced in 45 % of the cases in S groups versus 18,4 % in P group. Global impression of efficacy was largely in favor of S; failure was noted in half of the cases in P group and only in 1/5th of the cases in S group. Side‐effects were rare and minor. S 10 mg/day monotherapy is statistically superior to placebo in improving de novo P. P. during the first three months treatment. Motor symptoms rapidly improve; mood is only modified after 3 months. S appears to be well tolerated. S may be considered as a good candidate for the initial treatment of P. P.</div></front></TEI><affiliations><list><country><li>France</li></country><settlement><li>Rennes</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name></noRegion><name sortKey="Cougnard, J" sort="Cougnard, J" uniqKey="Cougnard J" first="J." last="Cougnard">J. Cougnard</name><name sortKey="Neukirch, H" sort="Neukirch, H" uniqKey="Neukirch H" first="H-C." last="Neukirch">H-C. Neukirch</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000299 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000299 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:28655FDC6F1264C54FEFD8055B0D549CF08F5B32
|texte= Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT)
}}
| This area was generated with Dilib version V0.6.23. |  |